<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Dental</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>‘Most complete’ map of oral microbiome enables links to systemic disease</title>
      <description>
        <![CDATA[South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in <em>Cell Host & Microbe</em> on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told <em>BioWorld.</em>]]>
      </description>
      <guid>http://www.bioworld.com/articles/726351</guid>
      <pubDate>Tue, 18 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726351-most-complete-map-of-oral-microbiome-enables-links-to-systemic-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Nov-2020/Science-microbiome-11-5.webp?t=1604592414" type="image/png" medium="image" fileSize="553641">
        <media:title type="plain">Microbiome illustration</media:title>
        <media:description type="plain">Credit: Darryl Leja, NHGRI</media:description>
      </media:content>
    </item>
    <item>
      <title>‘Most complete’ map of oral microbiome enables links to systemic disease</title>
      <description>
        <![CDATA[South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in <em>Cell Host & Microbe</em> on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told <em>BioWorld.</em>]]>
      </description>
      <guid>http://www.bioworld.com/articles/726031</guid>
      <pubDate>Thu, 13 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726031-most-complete-map-of-oral-microbiome-enables-links-to-systemic-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Nov-2020/Science-microbiome-11-5.webp?t=1604592414" type="image/png" medium="image" fileSize="553641">
        <media:title type="plain">Microbiome illustration</media:title>
        <media:description type="plain">Credit: Darryl Leja, NHGRI</media:description>
      </media:content>
    </item>
    <item>
      <title>South Korea ramping up investment in medical device R&amp;D</title>
      <description>
        <![CDATA[A four-way interagency initiative in South Korea, started in 2020, is working to bolster funding for the local medical device industry and grow homegrown devices for the global market. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/725959</guid>
      <pubDate>Tue, 11 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725959-south-korea-ramping-up-investment-in-medical-device-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/South-Korea-flag-with-stock-chart-gold-coins.webp?t=1749843713" type="image/jpeg" medium="image" fileSize="608352">
        <media:title type="plain">South Korea flag with stock chart, gold coins</media:title>
      </media:content>
    </item>
    <item>
      <title>D-human β defensin 3 is periodontitis treatment hopeful</title>
      <description>
        <![CDATA[Antimicrobial peptides such as human β-defensin 3 (hBD3) have shown promise as a treatment for periodontitis; however, their poor stability and high production costs have hindered their clinical translation until now. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/725051</guid>
      <pubDate>Fri, 10 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725051-d-human-defensin-3-is-periodontitis-treatment-hopeful</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Scientist-microscope-dropper.webp?t=1682529627" type="image/png" medium="image" fileSize="550680">
        <media:title type="plain">Scientist, microscope and dropper</media:title>
      </media:content>
    </item>
    <item>
      <title>Tetratherix lists on ASX in $25M IPO</title>
      <description>
        <![CDATA[Tetratherix Ltd. raised AU$45 million (US$25 million) in its IPO on the Australian Securities Exchange (ASX:TTX) to support clinical development of its Tetramatrix polymer biomaterial platform to support bone regeneration, tissue spacing and tissue healing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721140</guid>
      <pubDate>Mon, 30 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721140-tetratherix-lists-on-asx-in-25m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Tetratherix-Tetramatrix-30june25.webp?t=1751318592" type="image/jpeg" medium="image" fileSize="240574">
        <media:title type="plain">Tetratherix Tetramatrix</media:title>
        <media:description type="plain">Tetratherix’s Tetramatrix polymer biomaterial is delivered as a liquid. Credit: Tetratherix</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA takes a bite out of confusion with four new dental guidances</title>
      <description>
        <![CDATA[The U.S. FDA has guidances on the books for dental products, but the it unleashed a quartet of guidances – ceramics and cements used in dental procedure – for dental products on the final Friday of September 2024. The agency also issued a guidance without comment – unusual for the FDA – for the well-known, terror-striking pneumatic dental hand tool.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712654</guid>
      <pubDate>Mon, 30 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712654-fda-takes-a-bite-out-of-confusion-with-four-new-dental-guidances</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dental/Mouth--Dental-Disorders.webp?t=1588881428" type="image/png" medium="image" fileSize="401735">
        <media:title type="plain">Dental X-ray</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA to convene advisory meeting on generative AI-enabled devices</title>
      <description>
        <![CDATA[The Nov. 20-21 meeting of the digital health advisory committee will discuss the use of generative artificial intelligence algorithms in medical devices with a focus on the total product life cycle – a theme that suggests a concern on the agency’s part regarding the reliability of these algorithms’ output.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712235</guid>
      <pubDate>Mon, 16 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712235-fda-to-convene-advisory-meeting-on-generative-ai-enabled-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-binary-science-medical-research.webp?t=1698157716" type="image/jpeg" medium="image" fileSize="555712">
        <media:title type="plain">Science and medicine icons with head made of computer code</media:title>
      </media:content>
    </item>
    <item>
      <title>Planmeca hit with PHOSITA blues in patent litigation with Osseo</title>
      <description>
        <![CDATA[The U.S. Court of Appeals for the Federal Circuit shot down Planmeca’s argument that expert testimony provided by Osseo was disqualified because the expert was not a PHOSITA at the time the patented articles were developed, leaving Planmeca with a negative verdict in excess of $2 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711950</guid>
      <pubDate>Thu, 05 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711950-planmeca-hit-with-phosita-blues-in-patent-litigation-with-osseo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/regulatory-washington-us-flag.webp?t=1588689518" type="image/png" medium="image" fileSize="594023">
        <media:title type="plain">U.S. flag on columned building</media:title>
      </media:content>
    </item>
    <item>
      <title>​US FDA wary of predicate devices in draft guidance for jawbone grafts​</title>
      <description>
        <![CDATA[The U.S. FDA issued a draft guidance for premarket applications for class II bone grafting devices, a policy that would supplement a guidance issued nearly two decades ago.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706893</guid>
      <pubDate>Mon, 01 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706893-us-fda-wary-of-predicate-devices-in-draft-guidance-for-jawbone-grafts</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-2-Launchpad-Dental-bone-graft.webp?t=1591139398" type="image/png" medium="image" fileSize="1333902">
        <media:title type="plain">Image from pilot animal study</media:title>
        <media:description type="plain">Jawbone from study with the optimized Tetranite (TN) bone graft 
formulation on the left, which is adhesive, vs. the standard-of-care treatment to the right, which is autograft (AG) particulate graft 
material contained into the bone defect using a membrane 
with tacks. Credit: Launchpad Medical LLC</media:description>
      </media:content>
    </item>
    <item>
      <title>The University of Hong Kong divulges new silver complexes for dental caries</title>
      <description>
        <![CDATA[The University of Hong Kong has synthesized silver complexes with high aqueous solubility reported to be useful for the treatment of dental caries.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694913</guid>
      <pubDate>Wed, 08 Mar 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694913-the-university-of-hong-kong-divulges-new-silver-complexes-for-dental-caries</link>
    </item>
    <item>
      <title>Virtici receives SBIR award to advance VTC-886 for periodontitis</title>
      <description>
        <![CDATA[Virtici LLC has been granted a Small Business Innovation Research (SBIR) award by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to advance VTC-886, a first-in-class small molecule for the prevention of <em>Porphyromonas gingivalis</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690350</guid>
      <pubDate>Fri, 07 Oct 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690350-vertici-receives-sbir-award-to-advance-vtc-886-for-periodontitis</link>
    </item>
    <item>
      <title>Orthocell inks global deal with Biohorizons for dental collagen membrane worth $16M</title>
      <description>
        <![CDATA[Orthocell Ltd. landed its first global licensing deal for its regenerative collagen medical device with Biohorizons Inc., one of the largest dental implant companies in the world. The licensing deal comes on the heels of the Perth, Australia-based company reporting final data from its nerve reconstruction study that showed patients continued to improve between 12- and 24-months post-treatment with its regenerative nerve repair device Remplir.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520405</guid>
      <pubDate>Tue, 05 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520405-orthocell-inks-global-deal-with-biohorizons-for-dental-collagen-membrane-worth-16m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-deal-merger.webp?t=1588276766" type="image/png" medium="image" fileSize="334962">
        <media:title type="plain">Business people with hands atop a digital globe</media:title>
      </media:content>
    </item>
    <item>
      <title>MKX regulates periodontal ligament homeostasis</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/687289</guid>
      <pubDate>Tue, 15 Feb 2022 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/687289-mkx-regulates-periodontal-ligament-homeostasis</link>
    </item>
    <item>
      <title>Regulating fibrin-neutrophil interaction for controlling periodontitis</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/686877</guid>
      <pubDate>Fri, 07 Jan 2022 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/686877-regulating-fibrin-neutrophil-interaction-for-controlling-periodontitis</link>
    </item>
    <item>
      <title>Wishbone raises $3M to ramp commercialization of its dental implant bone regeneration technology</title>
      <description>
        <![CDATA[PARIS – Wishbone SA closed a $3 million funding round, which should allow it to obtain the CE mark prior to launching its range of products in Europe based on bone regeneration technology for reconstructive dental surgery. “Thanks to this round, we are ramping scale and moving from R&D to the commercialization phase in Europe,” Daniel Bee, CEO of Wishbone, told <em>BioWorld.</em>]]>
      </description>
      <guid>http://www.bioworld.com/articles/514000</guid>
      <pubDate>Mon, 06 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514000-wishbone-raises-3m-to-ramp-commercialization-of-its-dental-implant-bone-regeneration-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dental/Mouth--Dental-Disorders.webp?t=1588881428" type="image/png" medium="image" fileSize="401735">
        <media:title type="plain">Dental X-ray</media:title>
      </media:content>
    </item>
    <item>
      <title>AFYX Therapeutics presents preclinical data on anti-TNF antibody delivery through adhesive patch</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/685510</guid>
      <pubDate>Fri, 10 Sep 2021 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/685510-afyx-therapeutics-presents-preclinical-data-on-anti-tnf-antibody-delivery-through-adhesive-patch</link>
    </item>
    <item>
      <title>Phase II study of AMY-101 for periodontal inflammation and gingivitis meets endpoints</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/682776</guid>
      <pubDate>Fri, 19 Mar 2021 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/682776-phase-ii-study-of-amy-101-for-periodontal-inflammation-and-gingivitis-meets-endpoints</link>
    </item>
    <item>
      <title>Zimmer Biomet streamlines focus with spinoff of spine and dental businesses</title>
      <description>
        <![CDATA[Zimmer Biomet Holdings Inc. continued its transformation, disclosing Friday that it will spin off its spine and dental businesses into a separate, publicly traded company. The move will enable the independent company, identified as Newco, to pursue strategies and growth in spine and dental solutions that have not been a major focus for Zimmer Biomet, while allowing the latter to focus on high-growth orthopedic segments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503354</guid>
      <pubDate>Mon, 08 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503354-zimmer-biomet-streamlines-focus-with-spinoff-of-spine-and-dental-businesses</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
    <item>
      <title>Orthocell’s stock soars following FDA 510(k) clearance of regenerative collagen medical device</title>
      <description>
        <![CDATA[PERTH, Australia &ndash; Perth-based regenerative medicine company Orthocell Ltd. saw its shares rise 27% on the heels of its first U.S. approval for its collagen medical device for dental guided bone and soft tissue regeneration applications. &ldquo;It&rsquo;s an important milestone for us, and one that came quicker than I was expecting it to come,&rdquo; Orthocell CEO Paul Anderson told <em>BioWorld</em>. The company submitted its 510(k) application to the FDA in May, and he was expecting approval by the middle of 2021.]]>
      </description>
      <guid>http://www.bioworld.com/articles/502426</guid>
      <pubDate>Thu, 14 Jan 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/502426-orthocells-stock-soars-following-fda-510k-clearance-of-regenerative-collagen-medical-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/5-22-Orthocell-CEO-and-team.webp?t=1590179441" type="image/png" medium="image" fileSize="969245">
        <media:title type="plain">Orthocell CEO with employees in the lab</media:title>
        <media:description type="plain">CEO Paul Anderson (left). Credit: Orthocell Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Nabota demonstrates palliative effect on bruxism </title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/679052</guid>
      <pubDate>Wed, 05 Aug 2020 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/679052-nabota-demonstrates-palliative-effect-on-bruxism</link>
    </item>
    <item>
      <title>Launchpad Medical nabs $1.8M grant for pivotal animal study of dental bone graft solution</title>
      <description>
        <![CDATA[Lowell, Mass.-based startup Launchpad Medical LLC has picked up an additional $1.8 million grant from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center to advance the development of its bone graft solution. The company plans to use the funds to conduct a pivotal animal study of the injectable biomaterial, which will pave the way for a U.S. FDA-approved clinical trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435528</guid>
      <pubDate>Tue, 02 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435528-launchpad-medical-nabs-18m-grant-for-pivotal-animal-study-of-dental-bone-graft-solution</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-2-Launchpad-Dental-bone-graft.webp?t=1591139398" type="image/png" medium="image" fileSize="1333902">
        <media:title type="plain">Image from pilot animal study</media:title>
        <media:description type="plain">Jawbone from study with the optimized Tetranite (TN) bone graft 
formulation on the left, which is adhesive, vs. the standard-of-care treatment to the right, which is autograft (AG) particulate graft 
material contained into the bone defect using a membrane 
with tacks. Credit: Launchpad Medical LLC</media:description>
      </media:content>
    </item>
    <item>
      <title>Ortek fills cavity in dental care with early caries detection system</title>
      <description>
        <![CDATA[Ortek Therapeutics Inc., of Roslyn Heights, N.Y., has officially launched its electronic early cavity detection system, the Ortek-ECD. The U.S. FDA-cleared device can detect dental lesions before they show up on X-rays, enabling less invasive treatment and preventing greater damage to the tooth structure. Ortek holds the exclusive license for the device which was developed at Stony Brook University School of Dental Medicine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435286</guid>
      <pubDate>Thu, 21 May 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435286-ortek-fills-cavity-in-dental-care-with-early-caries-detection-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/5-21-Ortek-ECD.webp?t=1590098490" type="image/png" medium="image" fileSize="445621">
        <media:title type="plain">Early cavity detection (ECD) system product image</media:title>
        <media:description type="plain">Orteck-ECD with accessories. Credit: Ortek Therapeutics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA OKs Align Technology’s Itero Element 5D dental scanner</title>
      <description>
        <![CDATA[San Jose, Calif.-based Align Technology Inc. has won the FDA&rsquo;s nod for its Itero Element 5D imaging system. The company said the Itero Element 5D is the first intraoral scanner with near-infrared imaging (NIRI) technology that visualizes the internal structure of the tooth in real time. The FDA cleared the device for the detection of interproximal caries lesions above the gingiva and for monitoring the progress of such lesions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433962</guid>
      <pubDate>Wed, 25 Mar 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/433962-fda-oks-align-technologys-itero-element-5d-dental-scanner</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-25-Align-itero-element-5d.webp?t=1585170625" type="image/png" medium="image" fileSize="541269">
        <media:title type="plain">3-25-Align-itero-element-5d.png</media:title>
        <media:description type="plain">Itero Element 5D imaging system. Credit: Align Technology Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>University of California patents compounds for periodontal disease</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/674045</guid>
      <pubDate>Tue, 01 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/674045-university-of-california-patents-compounds-for-periodontal-disease</link>
    </item>
    <item>
      <title>Danaher hits road to IPO dental business as its spinout Fortive is set to split in two</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/430503</guid>
      <pubDate>Fri, 06 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430503-danaher-hits-road-to-ipo-dental-business-as-its-spinout-fortive-is-set-to-split-in-two</link>
    </item>
    <item>
      <title>Amyndas opens phase IIa study of AMY-101 in periodontal inflammation</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/673527</guid>
      <pubDate>Thu, 29 Aug 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/673527-amyndas-opens-phase-iia-study-of-amy-101-in-periodontal-inflammation</link>
    </item>
    <item>
      <title>U.S. approval for Otezla to treat oral ulcers associated with Behcet's disease</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/672880</guid>
      <pubDate>Mon, 22 Jul 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/672880-u-s-approval-for-otezla-to-treat-oral-ulcers-associated-with-behcet-s-disease</link>
    </item>
    <item>
      <title>Gene Techno Science and OrthoRebirth collaborate to develop treatment for cleft lip/cleft palate</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/671644</guid>
      <pubDate>Mon, 13 May 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/671644-gene-techno-science-and-orthorebirth-collaborate-to-develop-treatment-for-cleft-lip-cleft-palate</link>
    </item>
    <item>
      <title>Mutations in ADAMTSL1 are responsible for the pathogenesis of mandibular prognathism</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/670919</guid>
      <pubDate>Mon, 01 Apr 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/670919-mutations-in-adamtsl1-are-responsible-for-the-pathogenesis-of-mandibular-prognathism</link>
    </item>
    <item>
      <title>Vaccine targets generated by cell-free protein synthesis limit P. gingivalis-elicited oral bone loss</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/670451</guid>
      <pubDate>Mon, 04 Mar 2019 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/670451-vaccine-targets-generated-by-cell-free-protein-synthesis-limit-p-gingivalis-elicited-oral-bone-loss</link>
    </item>
  </channel>
</rss>
